We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis Reports Positive Long-Term Data From Cosentyx Trials
Read MoreHide Full Article
Novartis (NVS - Free Report) reported encouraging five-year data from ongoing extensions of the phase III studies, FUTURE 1 and MEASURE 1, on Cosentyx in patients suffering from psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
FUTURE 1 is a two-year, multi-center, randomized, placebo-controlled phase III pivotal study to evaluate the efficacy of Cosentyx in patients with active PsA while MEASURE 1 is a two-year, multi-center, randomized, placebo-controlled phase III study assessing the efficacy and safety of Cosentyx in patients with active AS
The new data will be presented at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, United States.
The new data reinforces Cosentyx’s efficacy as results show that the data provides sustained improvements in the signs and symptoms of PsA and AS for five years. Data from the FUTURE 1 study demonstrated that 83% and 94% of PsA patients achieved total resolution of enthesitis and dactylitis, respectively. Over 80% of patients who entered the extension phases of both studies completed five years with a safety profile consistent with previous reports.
The data further add to SCULPTURE study data, which showed that two thirds of patients on Cosentyx reported no impact of skin disease on their quality of life over five years.
The uptake of Cosentyx has been strong and the company has grabbed market share from rivals, AbbVie’s (ABBV - Free Report) Humira and Amgen’s (AMGN - Free Report) Enbrel. Cosentyx achieved multi-blockbuster drug status in 2017 on the back of strong growth in its three approved indications – moderate-to-severe plaque psoriasis, AS and psoriatic arthritis.
Cosentyx also obtained FDA approval on PsA efficacy labeling supplement to include radiographic response data from the FUTURE 5 study.
Of late, Novartis is redirecting its focus to its core areas of growth. Earlier, the company announced that it intends to spin-off its ophthalmology division, Alcon, into a separately-traded standalone company to grow as a medicines company solely.
The Alcon business was not performing per management’s expectations. Although it did witness some recovery, the company decided to spin-off the same in order to focus better on its legacy drug business. The company also exited its antibacterial business. Earlier, Novartis had divested its stake in the OTC joint venture with GlaxoSmithKline (GSK - Free Report) for $13 billion.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Novartis Reports Positive Long-Term Data From Cosentyx Trials
Novartis (NVS - Free Report) reported encouraging five-year data from ongoing extensions of the phase III studies, FUTURE 1 and MEASURE 1, on Cosentyx in patients suffering from psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
FUTURE 1 is a two-year, multi-center, randomized, placebo-controlled phase III pivotal study to evaluate the efficacy of Cosentyx in patients with active PsA while MEASURE 1 is a two-year, multi-center, randomized, placebo-controlled phase III study assessing the efficacy and safety of Cosentyx in patients with active AS
The new data will be presented at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, United States.
The new data reinforces Cosentyx’s efficacy as results show that the data provides sustained improvements in the signs and symptoms of PsA and AS for five years. Data from the FUTURE 1 study demonstrated that 83% and 94% of PsA patients achieved total resolution of enthesitis and dactylitis, respectively. Over 80% of patients who entered the extension phases of both studies completed five years with a safety profile consistent with previous reports.
The data further add to SCULPTURE study data, which showed that two thirds of patients on Cosentyx reported no impact of skin disease on their quality of life over five years.
The uptake of Cosentyx has been strong and the company has grabbed market share from rivals, AbbVie’s (ABBV - Free Report) Humira and Amgen’s (AMGN - Free Report) Enbrel. Cosentyx achieved multi-blockbuster drug status in 2017 on the back of strong growth in its three approved indications – moderate-to-severe plaque psoriasis, AS and psoriatic arthritis.
Cosentyx also obtained FDA approval on PsA efficacy labeling supplement to include radiographic response data from the FUTURE 5 study.
Of late, Novartis is redirecting its focus to its core areas of growth. Earlier, the company announced that it intends to spin-off its ophthalmology division, Alcon, into a separately-traded standalone company to grow as a medicines company solely.
The Alcon business was not performing per management’s expectations. Although it did witness some recovery, the company decided to spin-off the same in order to focus better on its legacy drug business. The company also exited its antibacterial business. Earlier, Novartis had divested its stake in the OTC joint venture with GlaxoSmithKline (GSK - Free Report) for $13 billion.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>